About Genelabs Technologies
is discovering compounds that selectively inhibit replication of the hepatitis C virus, and advancing preclinical development of compounds from this hepatitis C virus drug discovery program, while also developing a late-stage product for lupus. They aim to generate either first-in-class or best-in-class products that will address diseases for which current therapies are inadequate.
Genelabs Technologies Patents
Genelabs Technologies has filed 2 patents.
Androgens and anabolic steroids, Androstanes, G protein coupled receptors, Transcription factors, Ketones
Androgens and anabolic steroids, Androstanes, G protein coupled receptors, Transcription factors, Ketones
Latest Genelabs Technologies News
Sep 2, 2021
September 02, 2021 01:05 PM Eastern Daylight Time CAMBRIDGE, Mass.--( BUSINESS WIRE )--Civetta Therapeutics, LLC, a biotechnology company focused on developing a pipeline of therapies that target beta-propeller proteins, today announced that Christopher D. Roberts, Ph.D., has been appointed as Chief Executive Officer. Dr. Roberts, who most recently served as Chief Scientific Officer of Black Diamond Therapeutics, brings more than 20 years of leadership experience discovering and developing novel therapies for oncology, immunology, virology and other indications. “Civetta has developed a unique discovery platform designed to rigorously investigate, validate and drug beta-propeller proteins. Because propeller domains are ubiquitous and play critical functions in pathways that are known contributors to pathogenesis, they provide broad opportunity as therapeutic targets,” said Dr. Roberts. “I’m impressed by the work the team has done advancing its lead programs and platform. I look forward to joining the Civetta team in the discovery and development of novel, first-in-class therapies that can help patients across a variety of disease areas, from cancer, inflammation and immunology to neurodegeneration and metabolic disease.” Cameron Wheeler, Ph.D., who was serving as Chief Executive Officer at Civetta and is a Partner in the Biotherapeutics Group at Deerfield Management Company, will continue to serve as chairman of Civetta’s board of directors. “The team at Civetta has done great work taking the early insights into beta-propeller science made by our founders at the Broad Institute and the Dana-Farber Cancer Institute and advancing them, to better understand their role in a variety of diseases,” said Dr. Wheeler. “We see broad potential for targeting beta-propeller proteins and we’re working to identify novel, near-term therapeutics and establish the leading beta-propeller targeting platform in the industry. Attracting top talent like Chris will continue to be critical as we accelerate and expand our programs and pipeline.” Prior to joining Black Diamond, Chris served as an Entrepreneur in Residence at SR One, the corporate venture capital arm of GlaxoSmithKline (GSK). Prior to SR One, Chris was the Vice President (VP) of Chemistry and Early Development at Syros Pharmaceuticals, Inc., a publicly traded biotechnology company focused on gene control and drugging transcription, where he built and led a variety of discovery and development functions and helped guide two oncology assets into clinical development. Prior to joining Syros, Chris held numerous positions of increasing responsibility at GSK, including VP and Head of the Host Defense Discovery Performance Unit, and also led multiple clinical development projects. He joined GSK as Senior Director of Hepatitis C Virus (HCV) Medicinal Chemistry via its acquisition of Genelabs Technologies. As a medicinal chemist at Genelabs, Chris was significantly involved in establishing Genelabs’ HCV research focus. His work has been extensively published. Chris earned a Ph.D. in Organic Chemistry from the University of California, Riverside, and completed a post-doctoral fellowship at the University of Bern, Switzerland. He graduated with a B.A. in Chemistry from Whitworth University. About Civetta Civetta is a biotechnology company focused on the development of therapies that target beta-propeller domains to treat cancer and other diseases. The company was founded based on the pivotal insights into beta-propeller domains made by its founders , which helped elucidate beta-propeller domain functionality and their potential for therapeutic intervention in oncology as well as neurodegeneration, metabolic disease and other disease areas. Civetta is funded by Deerfield Management Company and is based in Cambridge, MA. For more information, please visit www.civettatherapeutics.com . Contacts
Genelabs Technologies Frequently Asked Questions (FAQ)
When was Genelabs Technologies founded?
Genelabs Technologies was founded in 1983.
Where is Genelabs Technologies's headquarters?
Genelabs Technologies's headquarters is located at 505 Penobscot Drive, Redwood City.
What is Genelabs Technologies's latest funding round?
Genelabs Technologies's latest funding round is Unattributed VC - II.
How much did Genelabs Technologies raise?
Genelabs Technologies raised a total of $17.59M.
Who are the investors of Genelabs Technologies?
Investors of Genelabs Technologies include Heights Capital Management, SF Capital Group, BVF Partners, First Eagle Investment Management, Centrecourt and 13 more.
Who are Genelabs Technologies's competitors?
Competitors of Genelabs Technologies include Applied Genetic Technologies, Lycera, IRX Therapeutics, Romark Global Pharma, Celsis International and 7 more.
Compare Genelabs Technologies to Competitors
Active Pass is a Canadian biotechnology company that is engaging in genomic-based drug discovery and is developing drugs that inhibit ABC transporters. ABC or (ATP binding cassette) is a term that describes the interconnected group of molecular engines or pumps that function as a transportation system which moves compounds across the biological membranes. These ABCs are very closely associated with human diseases like Alzheimer's disease, diabetes, asthma, and hypertension. The Active Pass management team is an accomplished group with experience in many aspects of drug discovery and development. Besides employing full time pharmaceutical development professionals, Active Pass has made wise use of a group of several key partnerships with different pharmaceutical groups. The company cultivates these partnerships in order to access new capabilities or expertise to advance the company's own technologies. More specifically, these partnerships include the Vaccines and Infectious Diseases Organization as well as the National Institute of Health). The company hopes to add new personnel to cover emerging areas of emphasis like clinical and regulatory affairs, business development and finance as they grow.
Welichem Biotech Inc. ("Welichem", TSX-V: WBI) is engaged in the discovery and development of small molecule therapeutics. Using its Symbiochem technology platform, the Company has developed a robust pipeline of patent-protected compounds that target autoimmune/inflammatory diseases and cancers. Welichem's lead drug candidate, WBI-1001, targets autoimmune/inflammatory skin disorders, such as psoriasis and eczema. A phase I clinical trial of WBI-1001, done in Montreal, in patients with psoriasis has shown a very good safety profile and promising efficacy. As well, the application of WBI-1001 cream against atopic dermatitis (a type of eczema) in a phase IIa clinical trial also has been completed in Canada, with the final report pending in the third quarter of 2008. Welichem plans to all the necessary Phase II Clinical Trials against psoriasis and eczema in the near future. In the company's pipeline, WBI-1001 related compounds are being evaluated also for their therapeutic potential against other autoimmune diseases such as, inflammatory bowel disease and rheumatoid arthritis. Welichem's other lead drug candidate, WBI-2100, selectively targets certain types of hard-to-treat cancerous tumours. This is achieved in part through inhibition of angiogenesis and metastasis. Animal tests have shown that WBI-2100 is effective as a monotherapy and also in increasing the effectiveness of several commonly used chemotherapeutic products. The uniqueness of this small molecule cancer chemotherapeutic is that in pre-clinical studies it increases the number of neutrophils in the peripheral blood. The boosting of neutrophils in animal studies in the presence of the cancer therapeutic, cyclophosphamide, supports its potential therapeutic application for chemotherapy induced neutropenia. With its proven Symbiochem; technology platform, Welichem will advance its pipeline of drug candidates at a rate and time commensurate with resources and target need, and is in a strong position to contribute effectively to productive drug discovery and development partnerships.
Bikam supplies all kinds of scientific and professional literature. It offers a subscription order for government and non-government organizations, commercial representatives, higher educational institutions, and more. It was founded in 1996 and is based in Sofia, Bulgaria.
VivoPath is a preclinical screening company, offering the company's clients discovery and development services for in vivo testing. VivoPath aims to provide integrated in vivo studies led by established experts in drug development. Efficacy is established for animal models in the areas of metabolic disease, inflammation, neurodegenerative disease, and infectious diseases. Formulation screening is carried out to select the most appropriate delivery system for administration. Pharmacokinetic evaluation is carried out to assess exposure and bioavailability. Tolerability is assessed with evaluations of clinical signs, clinical chemistry and hematology. The resulting program aims to deliver the client an in vivo therapeutic index (TI) report on which to assess candidates for subsequent development. VivoPath can also help clients at any individual step in this preclinical screening process. VivoPath's commitment is to provide scientific expertise in in vivo drug discovery in order to increase productivity from research into drug development.
Kubota Vision is a pharmaceutical company that specializes in drug discovery and devices. It helps treat sight-threatening ophthalmic diseases. It was founded in 2002 and is based in Seattle, Washington. It is a subsidiary of Kubota Pharmaceutical Holdings.
Sequoia Sciences is a clinical-stage pharmaceutical company that operates in the healthcare industry. The company focuses on the discovery and development of novel vaccines to prevent bacterial infections, including recurrent urinary tract infections, and the treatment of certain cancers and lung infections associated with cystic fibrosis using small molecules. Its primary customer segments include the healthcare and pharmaceutical industries. It is based in St. Louis, Missouri.